openPR Logo
Press release

Orphan Drugs Market Size Is Projected To Reach USD 241610 Million By 2027

01-04-2023 05:48 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: Valuates Reports

Orphan Drugs Market Size Is Projected To Reach USD 241610 Million

Orphan Drugs Market Segment by Type - Oncology, Gastrointestinal, Pulmonary, Neurology, Hematology, Cardio-vascular, Metabolic Disorders, Endocrinology, Infectious Diseases, Others, Application - Hospital Pharmacies, Retail pharmacies, Others. The report covers global opportunity analysis and industry forecasts from 2021 to 2027.

The global Orphan Drugs market size is projected to reach USD 241610 million by 2027, from USD 122720 million in 2020, at a CAGR of 9.7% during 2021-2027.

Major Factors Driving The Growth Of The Orphan Drugs Market are

Government authorities in numerous nations throughout the world are pushing the research and marketing of these treatments, as well as giving orphan drugs market exclusivity. This in turn is expected to drive the orphan drug market.

For a variety of reasons, the orphan medicine market has become increasingly lucrative. Clinical trials for orphan medications are significantly less expensive than for other diseases since trial sizes are naturally smaller than for more common diseases with larger patient populations. Orphan drugs have an advantage in regulatory evaluation because of their small clinical trials and lack of competition.

Additionally, the market is expected to rise significantly due to an increase in the number of medications developed for uncommon blood illnesses and diseases previously thought to be incurable.

Get Your Sample Today: https://reports.valuates.com/request/sample/QYRE-Auto-29S2943/Global_Orphan_Drugs_Market

TRENDS INFLUENCING THE GROWTH OF ORPHAN DRUGS MARKET

An orphan drug is a pharmaceutical product used for the diagnosis, prevention, and treatment of various rare disorders or diseases, according to the European Organization for Rare Diseases. These diseases are distinct from other diseases in that they have a very low prevalence rate relative to other diseases, and so are purchased by a very tiny patient population. Government authorities in a number of nations around the world, on the other hand, are pushing the development and commercialization of these drugs. This in turn is expected to drive the growth of the orphan drug market.

The Orphan Drug Act (ODA) was passed by the US Food and Drug Administration (FDA) in 1983. The purpose was to promote the discovery of novel drugs for rare diseases. The Orphan Drug Act (ODA) permits developers to recoup costs by designating their drugs as orphans. This stimulates research into regions where there may be no therapy possibilities otherwise. If there is no commercially accessible treatment for a condition that affects more than 200,000 people, the ODA also covers medications.

Increasing R&D initiatives to propel worldwide orphan drug market expansion. Increased R&D investments by major companies for orphan drug development of unique product offerings is one of the essential driving factors prevailing in the worldwide market. Since the public's awareness of rare diseases has grown, a number of clinical-stage biopharmaceutical startups and existing market players have developed strong pipeline prospects for orphan medications in various stages of development. This growing interest in rare condition treatments is due to the fact that, in contrast to standard pharmaceutical portfolios, important pharmacological breakthroughs resulting in blockbuster drug development are far more likely in rare disorders.

Browse The Table Of Contents And List Of Figures At https://reports.valuates.com/reports/QYRE-Auto-29S2943/global-orphan-drugs

ORPHAN DRUGS MARKET SHARE ANALYSIS

Based on region, North America is expected to be the most lucrative. Throughout the forecast period, The increasing occurrence of uncommon illnesses is driving this region's market growth.

Based on type, the oncology segment is expected to be the most lucrative segment. The dominance is attributable to the existence of multiple oncology treatments in important businesses' product development pipelines, as well as a substantial number of orphan drugs devoted to cancer treatment.

Based on application, The hospital pharmacy segment is expected to be the most lucrative. The fundamental reason for this domination is that a considerable number of medications must be administered intravenously by skilled healthcare workers in hospitals.

Inquire For Customization: https://reports.valuates.com/request/customisation/QYRE-Auto-29S2943/Global_Orphan_Drugs_Market

Orphan Drugs Market Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2016-2027. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region. North America, Europe, China and Japan are the major regions studied in the research report.

Orphan Drugs Market By Company

● Novartis
● Bristol-Myers Squibb Company
● Celgene
● F. Hoffmann-La Roche
● Pfizer
● Sanofi
● Alexion Pharmaceuticals
● Eli Lilly and Company
● Novo Nordisk
● AstraZeneca
● Eisai
● Daiichi Sankyo Company
● Bayer
● GlaxoSmithKline
● Merck & Co
● Johnson & Johnson
● Biogen
● Takeda
● Amgen

Inquire For Chapter Cost: https://reports.valuates.com/request/chaptercost/QYRE-Auto-29S2943/Global_Orphan_Drugs_Market

Buy Now for Single User + Covid-19 Impact : https://reports.valuates.com/api/directpaytoken?rcode=QYRE-Auto-29S2943&lic=single-user

SUBSCRIPTION

We have introduced a tailor-made subscription for our customers. Please leave a note in the Comment Section to know about our subscription plans.

SIMILAR REPORTS

Orphan Diseases Market
https://reports.valuates.com/market-reports/QYRE-Auto-11H6214/global-orphan-diseases

Oncology/Cancer Drugs Market
https://reports.valuates.com/market-reports/ALLI-Auto-2O5/oncology-cancer-drugs

Nutritional Analysis Market
https://reports.valuates.com/reports/QYRE-Auto-33I2800/global-nutritional-analysis

Digital PCR Market
https://reports.valuates.com/reports/ALLI-Manu-4P27/digital-pcr

Antimicrobial Susceptibility Testing Market
https://reports.valuates.com/reports/ALLI-Manu-1E55/antimicrobial-susceptibility-testing

Valuates Reports
sales@valuates.com
For U.S. Toll-Free Call 1-(315)-215-3225
For IST Call +91-8040957137
WhatsApp: +91-9945648335
Website: https://reports.valuates.com
Twitter - https://twitter.com/valuatesreports
Sitemap: https://reports.valuates.com/sitemap/html/reports
https://reports.valuates.com/sitemap/html/reports/132
https://reports.valuates.com/sitemap/html/reports/133

Valuates offers in-depth market insights into various industries. Our extensive report repository is constantly updated to meet your changing industry analysis needs.
Our team of market analysts can help you select the best report covering your industry. We understand your niche region-specific requirements and that's why we offer customization of reports. With our customization in place, you can request for any particular information from a report that meets your market analysis needs.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Orphan Drugs Market Size Is Projected To Reach USD 241610 Million By 2027 here

News-ID: 2871495 • Views:

More Releases from Valuates Reports

2-Oxazolidinone Market Revenue, Insights, Overview, Outlook, Analysis | Valuates …
2-Oxazolidinone Market Size The global market for 2-Oxazolidinone was valued at US$ 732 million in the year 2024 and is projected to reach a revised size of US$ 916 million by 2031, growing at a CAGR of 3.3% during the forecast period. Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-1I12558/Global_2_Oxazolidinone_Market?utm_source=Openpr&utm_medium=Referral This report aims to provide a comprehensive presentation of the global market for 2-Oxazolidinone, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess
Strontium-88 Market Revenue, Insights, Overview, Outlook, Analysis | Valuates Re …
Strontium-88 Market Size The global market for Strontium-88 was valued at US$ 89 million in the year 2024 and is projected to reach a revised size of US$ 126 million by 2031, growing at a CAGR of 5.2% during the forecast period. Download Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-34T9158/Global_Strontium_Market?utm_source=Openpr&utm_medium=Referral This report aims to provide a comprehensive presentation of the global market for Strontium-88, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess
Cobalt Sulfate Heptahydrate Market Revenue, Insights, Overview, Outlook, Analysi …
Cobalt Sulfate Heptahydrate Market Size The global market for Cobalt Sulfate Heptahydrate was valued at US$ 449 million in the year 2024 and is projected to reach a revised size of US$ 729 million by 2031, growing at a CAGR of 6.9% during the forecast period. Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-19T19438/Global_Cobalt_Sulfate_Heptahydrate_Market?utm_source=Openpr&utm_medium=Referral The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments
Ultrasonic Fabric Cutting and Sealing Machine Market Revenue, Insights, Overview …
Ultrasonic Fabric Cutting and Sealing Machine Market Size The global market for Ultrasonic Fabric Cutting and Sealing Machine was valued at US$ 1200 million in the year 2024 and is projected to reach a revised size of US$ 2091 million by 2031, growing at a CAGR of 8.2% during the forecast period. Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-12M18905/Global_Ultrasonic_Fabric_Cutting_and_Sealing_Machine_Market?utm_source=Openpr&utm_medium=Referral This report aims to provide a comprehensive presentation of the global market for Ultrasonic Fabric Cutting and

All 5 Releases


More Releases for Orphan

Acquired Orphan Blood Disease Market
Acquired Orphan Blood Disease Market to reach over USD 18.93 billion by the year 2031 - Exclusive Report by InsightAce Analytic According to a new report by InsightAce Analytic, the "Acquired Orphan Blood Disease Market" in terms of revenue was estimated to be worth $8.65 billion in 2023 and is poised to reach $18.93 billion by 2031, growing at a CAGR of 10.47% from 2024 to 2031. Get Free Access to
Orphan Drugs Market Size to Hit $3199.3 Billion by 2028 | Orphan Drugs Industry …
Market Overview: According to our experience research team, Orphan Drugs Market was valued at USD 112.36 Billion in 2021, and the global Orphan Drugs industry is projected to reach a value of USD 3199.3 Billion by 2028, at a CAGR of 7.4% during the forecast period 2022-2028 Vantage Market Research is a collection of market research studies on several industries, such as Chemicals, semiconductors & Electronics, Food & Beverages Technology, Energy &
Orphan Drugs for Cancer Pipeline Analysis
A huge market opportunity is offered by small patient population which suffers from rare or orphan diseases. Among the category of new orphan drugs, Oncology account for the largest disease group in recent years. It has been observed that majority of the orphan drugs in the clinical stages are for rare cancer disease drugs, and are in the late stages of the pipeline. Some of the drugs are being developed
US Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the pharmaceuticals industry.
Europe Orphan Drugs Pipeline Analysis
“Europe Orphan Drugs Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles under Orphan Drugs status in Europe. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. The information for particular drug
Global Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US & Europe, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the